Displaying drugs 10226 - 10250 of 12439 in total
Tigapotide
Tigapotide is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid.
Investigational
Matched Description: … Tigapotide is a synthetic 15-mer peptide that is derived from the natural sequence of amino acids of ... the prostate secretory protein (PSP94), one of three predominant proteins found in human seminal fluid …
Cimlanod
Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).
Investigational
Matched Description: … Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of ... Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers). …
SYNB1891
SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult...
Investigational
Matched Description: … cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. ... SYNB1891 is a live, modified strain of the probiotic _Escherichia coli_ Nissle engineered to produce ... [A256733] SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 …
Dianexin
Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients).
Investigational
Matched Description: … Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin …
Terevalefim
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Matched Description: … of a Deceased Donor Kidney). ... Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients …
Etavopivat
Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.
Investigational
Matched Description: … the treatment of sickle cell disease. ... Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for …
UV1
UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit
Investigational
Matched Description: … of the hTERT subunit ... UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments …
Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these...
Investigational
Matched Description: … Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was ... developed using domains of viral structural proteins and a polyprotein protease. ... Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, …
SYNB1020
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 ... SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc. ... convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of …
PTI-801
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
Matched Description: … PTI-801 represents a new class of drugs to treat pain. ... It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. ... can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of …
XmAb 2513
XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.
Investigational
Matched Description: … a number of tumor cell types. ... It has been investigated for the treatment of hodgkin’s lymphoma. ... a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of …
BacTRL-spike
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to...
Investigational
Matched Description: … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum ... Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. ... As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled …
Cenderitide
Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.
Investigational
Matched Description: … Cenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of …
Suvratoxumab
Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
Investigational
Matched Description: … Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of …
DS-2325a
DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
Investigational
Matched Description: … DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome. …
PI-0824
Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide. People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort. Currently, most doctors who treat patients with PV will prescribe high-dose steroids...
Investigational
Matched Description: … The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only ... on the disease causing components of the immune system. ... Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. …
Gatralimab
Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment).
Investigational
Matched Description: … Gatralimab is under investigation in clinical trial NCT02389452 (Study of Safety and Efficacy of 6 Ml ... Synvisc-one (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial …
Varlitinib
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
Investigational
Matched Description: … Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients ... Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 ... Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and …
(1R,2S)-2-Phenylcyclopropanaminium
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Experimental
Matched Description: … A propylamine formed from the cyclization of the side chain of amphetamine. ... This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder …
VX-765
VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Investigational
Matched Description: … VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase ... VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions …
ALT-2074
An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.
Investigational
Matched Description: … Some indications of efficacy were demonstrated. ... its ability to mimic the function of glutathione peroxidase. ... BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of …
Probiorinse
Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136. This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.
Investigational
Matched Description: … [L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity ... Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation …
Drinabant
AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.
Investigational
Matched Description: … mechanism of action as rimonabant. ... AVE-1625 is also being developed for the treatment of Alzheimer disease. ... AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same …
Fucoxanthin
Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects....
Investigational
Matched Description: … action of fucoxanthin is not fully elucidated. ... an animal model of duodenal, skin, colon and liver cancer. ... of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). …
Menaquinone 6
Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2).
Investigational
Matched Description: … Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different …
Displaying drugs 10226 - 10250 of 12439 in total